OPRX OptimizeRx Corp

Nasdaq optimizerx.com


$ 15.89 $ -2.80 (-15.24 %)    

Friday, 07-Nov-2025 19:52:18 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 15.65
$ 18.37
$ 14.82 x 5
$ 21.31 x 2
$ 14.81 - $ 18.37
$ 3.78 - $ 22.25
1,014,822
na
304.55M
$ 2.03
$ 9,228.70
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2025 09-30-2025 10-Q
2 08-08-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-15-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 04-15-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-12-2023 03-31-2023 10-Q
12 03-10-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-04-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-08-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 03-26-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 03-12-2019 12-31-2018 10-K
29 11-05-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-02-2018 03-31-2018 10-Q
32 03-08-2018 12-31-2017 10-K
33 11-02-2017 09-30-2017 10-Q
34 08-01-2017 06-30-2017 10-Q
35 05-03-2017 03-31-2017 10-Q
36 03-08-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-08-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-15-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citizens-maintains-market-outperform-on-optimizerx-raises-price-target-to-24

Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target...

 optimizerx-sees-fy2026-sales-118000m-124000m-vs-118125m-est

OptimizeRx (NASDAQ:OPRX) sees FY2026 sales of $118.000 million-$124.000 million vs $118.125 million analyst estimate.

 optimizerx-raises-fy2025-sales-guidance-from-104000m-108000m-to-105000m-109000m-vs-106506m-est

OptimizeRx (NASDAQ:OPRX) raises FY2025 sales outlook from $104.000 million-$108.000 million to $105.000 million-$109.000 millio...

 optimizerx-q3-adj-eps-020-beats-004-estimate-sales-26067m-beat-23833m-estimate

OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.04 by 3...

 jmp-securities-maintains-market-outperform-on-optimizerx-raises-price-target-to-23

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price ...

Core News & Articles

Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar's Vast Nationwide OO...

 optimizerx-appoints-brendan-merrell-as-coo

OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life scie...

 jmp-securities-maintains-market-outperform-on-optimizerx-raises-price-target-to-20

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price ...

 stifel-maintains-buy-on-optimizerx-raises-price-target-to-18

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $16 to $18.

 optimizerx-stock-rallies-22-after-hours-thanks-to-q2-earnings-push

OptimizeRx's stock jumped 22.66% after hours following strong Q2 earnings that beat expectations and lifted the share price...

 optimizerx-raises-fy2025-sales-guidance-from-101000m-106000m-to-104000m-108000m-vs-103365m-est

2025 Financial OutlookThe Company is increasing its 2025 guidance and expects revenue to be between $104 million and $108 milli...

 optimizerx-q2-adj-eps-024-beats-002-estimate-sales-29195m-beat-22264m-estimate

OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.02 by 1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION